The hippocampus plays an important role in a number of normal physiological processes and in a variety of pathological conditions, including Alzheimer's disease and temporal lobe epilepsy. Development of a complete understanding of the molecular and cellular mechanisms involved in regulation of hippocampal function could lead to new strategies for treatment of these disorders. Until recently, it was thought that all of the actions of glutamate, the major excitatory neurotransmitter in the hippocampus, were mediated by activation of ligand-gated cation channels. However, it is now clear that glutamate also activates metabotropic glutamate receptors (mGluRs), that are coupled to effector systems through GTP binding proteins. mGluRs play a number of important roles in regulating cell excitability and synaptic transmission in the hippocampus. A complete understanding of both normal and pathological hippocampal function will require a detailed understanding of the roles of mGluRs in modulating hippocampal physiology and the molecular mechanisms involved in regulating signaling by members of this important receptor family. Eight m(GluR subtypes (mGluR1 - mGluR8) have been identified by molecular cloning. In the hippocampus, evidence suggests that m(GluR2, mGluR7 and mGluR8 are all localized on presynaptic glutamatergic nerve terminals where they may serve to inhibit glutamate release. However, the postulated roles of mGluR7 and mGluR8 in regulating transmission at specific hippocampal synapses have not been definitively established. We recently reported that mGluR- mediated regulation of glutamate release can be inhibited by activation of protein kinase C (PKC). However, at present, the mechanism by which PKC inhibits signaling by presynaptic mGluRs is not known. A series of studies is proposed in which a combination of anatomical, pharmacological, and genetic approaches will be used to rigorously test the hypothesis that mGluR7 and m(GluR8 serve as presynaptic receptors at two major hippocampal synapses. We will then employ biochemical, electrophysiological, and molecular approaches to rigorously test the hypothesis that activation of PKC inhibits the function of presynaptic mGluRs by directly phosphorylating the receptors and inhibiting receptor coupling to GTP binding proteins. These studies could lead to a fundamental advance in our understanding of the mechanisms involved in regulation hippocampal function and could have important implications regarding novel approaches to treatment of disorders involving pathological changes in the hippocampus.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
7R01NS031373-11
Application #
6617992
Study Section
Special Emphasis Panel (ZRG1-MDCN-3 (01))
Program Officer
Stewart, Randall
Project Start
1993-08-01
Project End
2005-03-06
Budget Start
2003-08-01
Budget End
2005-03-06
Support Year
11
Fiscal Year
2003
Total Cost
$339,750
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Pharmacology
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Doria, Juliana G; de Souza, Jessica M; Silva, Flavia R et al. (2018) The mGluR5 positive allosteric modulator VU0409551 improves synaptic plasticity and memory of a mouse model of Huntington's disease. J Neurochem 147:222-239
Yohn, Samantha E; Conn, P Jeffrey (2018) Positive allosteric modulation of M1 and M4 muscarinic receptors as potential therapeutic treatments for schizophrenia. Neuropharmacology 136:438-448
Stansley, Branden J; Conn, P Jeffrey (2018) The therapeutic potential of metabotropic glutamate receptor modulation for schizophrenia. Curr Opin Pharmacol 38:31-36
Joffe, Max E; Centanni, Samuel W; Jaramillo, Anel A et al. (2018) Metabotropic Glutamate Receptors in Alcohol Use Disorder: Physiology, Plasticity, and Promising Pharmacotherapies. ACS Chem Neurosci 9:2188-2204
Gogliotti, Rocco G; Senter, Rebecca K; Fisher, Nicole M et al. (2017) mGlu7 potentiation rescues cognitive, social, and respiratory phenotypes in a mouse model of Rett syndrome. Sci Transl Med 9:
Moehle, Mark S; Pancani, Tristano; Byun, Nellie et al. (2017) Cholinergic Projections to the Substantia Nigra Pars Reticulata Inhibit Dopamine Modulation of Basal Ganglia through the M4 Muscarinic Receptor. Neuron 96:1358-1372.e4
Walker, Adam G; Sheffler, Douglas J; Lewis, Andrew S et al. (2017) Co-Activation of Metabotropic Glutamate Receptor 3 and Beta-Adrenergic Receptors Modulates Cyclic-AMP and Long-Term Potentiation, and Disrupts Memory Reconsolidation. Neuropsychopharmacology 42:2553-2566
Gogliotti, Rocco G; Senter, Rebecca K; Rook, Jerri M et al. (2016) mGlu5 positive allosteric modulation normalizes synaptic plasticity defects and motor phenotypes in a mouse model of Rett syndrome. Hum Mol Genet 25:1990-2004
Niswender, Colleen M; Jones, Carrie K; Lin, Xin et al. (2016) Development and Antiparkinsonian Activity of VU0418506, a Selective Positive Allosteric Modulator of Metabotropic Glutamate Receptor 4 Homomers without Activity at mGlu2/4 Heteromers. ACS Chem Neurosci 7:1201-11
Senter, Rebecca K; Ghoshal, Ayan; Walker, Adam G et al. (2016) The Role of mGlu Receptors in Hippocampal Plasticity Deficits in Neurological and Psychiatric Disorders: Implications for Allosteric Modulators as Novel Therapeutic Strategies. Curr Neuropharmacol 14:455-73

Showing the most recent 10 out of 132 publications